EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype

Elina A Beleva iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242115717 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Elina A Beleva. Beteiligte Einrichtung: Clinic of Hematology, Military Medical Academy, 1606 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Myeloproliferative Disorders, Venous Thrombosis, Polycythemia Vera. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Splanchnic vein thrombosis (SVT) encompasses thrombosis in the vessels of the splanchnic basin and has a relatively rare occurrence with a reported frequency in the general population of 1–2%. An episode of seemingly unprovoked SVT almost always triggers a diagnostic work-up for a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), since atypical site thrombosis is a hallmark of MPN-associated thrombophilia. Primary myelofibrosis (PMF) is a rare MPN with an estimated incidence between 0.1 and 1/100,000 per year. Although prothrombotic tendency in PMF is not envisioned as a subject of specific therapeutic management, unlike other MPNs, such as polycythemia vera (PV) and essential thrombocythemia (ET), thrombotic risk and SVT prevalence in PMF may be comparably high. Additionally, unlike PV and ET, SVT development in PMF may depend more on procoagulant mechanisms involving endothelium than on blood cell activation. Emerging results from registry data also suggest that PMF patients with SVT may exhibit lower risk and better prognosis, thus highlighting the need for better thrombotic risk stratification and identifying a subset of patients with potential benefit from antithrombotic prophylaxis. This review highlights specific epidemiological, pathogenetic, and clinical features pertinent to SVT in myelofibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisMyeloproliferative DisordersVenous ThrombosisPolycythemia VeraThrombosisThrombocythemia, EssentialHumansPhenotype

Stichwörter der Autor:innen

myelofibrosismyeloproliferative disorderssplanchnic circulationvenous thrombosis

Autor:innen und Institutionen

  • Clinic of Hematology, Military Medical Academy, 1606 Sofia, Bulgaria.
  • QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.

ORCID-Profile: Elina A Beleva

Zitieren

APA

Beleva, E. A. (2023). Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242115717

Vancouver

Beleva EA. Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242115717

BibTeX
@article{Beleva2023,
  author = {Beleva, Elina A},
  title = {Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242115717}
}
Kostenlos starten →